JOMPAC

Journal of Medicine and Palliative Care (JOMPAC) is an open access scientific journal with independent, unbiased, and double-blind review under international guidelines. The purpose of JOMPAC is to contribute to the literature by publishing articles on health sciences and medicine.

EndNote Style
Index
Original Article
The importance of serum estrone level in cases of chronic venous insufficiency in the lower extremity
Aims: Chronic venous insufficiency (CVI) is a condition characterized by abnormal venous flow dynamics in the lower limbs and is associated with various risk factors such as pregnancy, age, obesity, and high estrogen states. One of these estrogens, estrone, is known to have cardioprotective effects. The study aimed to evaluate the relationship between estrone levels in women with CVI and healthy women.
Methods: Clinical and laboratory data from 39 women with CVI and 31 healthy women without CVI were collected. All participants underwent spectral Doppler examinations and combined B-mode imaging to assess the severity of CVI.
Results: The results showed a statistically significant increase in the diameter of the vena saphenous magna in the CVI group compared to the healthy control group (p<0.05). However, there were no significant differences in estrone levels between the two groups. Besides, significant correlations were observed between estrone levels and age (r: -0.351; p=0.028), BMI and age(r: 0.374; p=0.019), and BMI and abdominal circumference (r: 0.700; p<0.001) in the CVI group.
Conclusion: Our study suggests that estrone levels may have a protective effect on CVI pathogenesis. The observed effect of estrone on women with CVI may be attributed to its different receptor-level effects compared to estradiol. Further research is necessary to fully elucidate the contribution of estrone to CVI and its underlying mechanisms.


1. Baliyan V, Tajmir S, Hedgire SS, Ganguli S, Prabhakar AM. Lowerextremity venous reflux. Cardiovasc Diagn Ther. 2016;6(6):533-543. doi:10.21037/cdt.2016.11.14
2. Kurz X, Kahn SR, Abenhaim L, et al. Chronic venous disordersof the leg: epidemiology, outcomes, diagnosis and management.Summary of an evidence-based report of the VEINES task force.Venous Insufficiency Epidemiologic and Economic Studies. IntAngiol. 1999;18(2):83-102.
3. Sadick NS. Predisposing factors of varicose and telangiectaticleg veins. J Dermatol Surg Oncol. 1992; 18(10):883-886.doi:10.1111/j.1524-4725.1992.tb02921.x
4. Fowkes FG, Lee AJ, Evans CJ, Allan PL, Bradbury AW, RuckleyCV. Lifestyle risk factors for lower limb venous reflux in thegeneral population: Edinburgh Vein Study. Int J Epidemiol.2001;30(4):846-852. doi:10.1093/ije/30.4.846
5. Gloviczki P, Comerota AJ, Dalsing MC, et al. The care of patientswith varicose veins and associated chronic venous diseases:clinical practice guidelines of the Society for Vascular Surgery andthe American Venous Forum. J Vasc Surg. 2011;53(5 Suppl):2S-48S. doi:10.1016/j.jvs.2011.01.079
6. Bromen K, Pannier-Fischer F, Stang A, Rabe E, Bock E, Jockel KH.Should sex specific differences in venous diseases be explainedby pregnancies and hormone intake? Gesundheitswesen.2004;66(3):170-174. Lassen sich geschlechtsspezifischeunterschiede bei venenerkrankungen durch schwangerschaftenund hormoneinnahme erklaren? doi:10.1055/s-2004-813019
7. Ciardullo AV, Panico S, Bellati C, et al. High endogenous estradiolis associated with increased venous distensibility and clinicalevidence of varicose veins in menopausal women. J Vasc Surg.2000;32(3): 544-549. doi:10.1067/mva.2000.107768
8. Hetemaki N, Mikkola TS, Tikkanen MJ, et al. Adipose tissueestrogen production and metabolism in premenopausal women.J Steroid Biochem Mol Biol. 2021;209:105849. doi:10.1016/j.jsbmb.2021.105849
9. Grow DR. Metabolism of endogenous and exogenousreproductive hormones. Obstet Gynecol Clin North Am. Sep2002;29(3):425-436. doi:10.1016/s0889-8545(02)00009-8
10. Seeger H, Mueck AO, Lippert TH. Effect of estradiol metaboliteson prostacyclin synthesis in human endothelial cell cultures. LifeSci. 1999;65(13):PL167-170. doi:10.1016/s0024-3205(99)00383-5
11. Selles J, Polini N, Alvarez C, Massheimer V. Novel action ofestrone on vascular tissue: regulation of NOS and COX activity.Steroids. 2005;70(4):251-256. doi:10.1016/j.steroids.2004.10.012
12. Massheimer V, Polini N, Alvarez C, Benozzi S, RauschembergerMB, Selles J. Signal transduction pathways involved innon-genomic action of estrone on vascular tissue. Steroids.2006;71(10):857-864. doi:10.1016/j.steroids.2006.05.015
13. Chervenak J. Bioidentical hormones for maturing women.Maturitas. 2009;64(2):86-89. doi:10.1016/j. maturitas.2009.08.002
14. Crescitelli MC, Rauschemberger MB, Cepeda S, SandovalM, Massheimer VL. Role of estrone on the regulation ofosteoblastogenesis. Mol Cell Endocrinol. 2019;498:110582.doi:10.1016/j.mce.2019. 110582
15. Serra R, Gallelli L, Perri P, et al. Estrogen receptors and chronicvenous disease. Eur J Vasc Endovasc Surg. 2016;52(1):114-118.doi:10.1016/j.ejvs.2016.04.020
16. Asbeutah AM, Al-Enezi M, Al-Sharifi NM, et al. Changes in thediameter and valve closure time of leg veins across the menstrualcycle. J Ultrasound Med. 2014;33(5):803-809.
17. Asbeutah AM, Al-Azemi M, Al-Sarhan S, Almajran A, AsfarSK. Changes in the diameter and valve closure time of legveins in primigravida women during pregnancy. J Vasc SurgVenous Lymphat Disord. 2015;3(2):147-153. doi:10.1016/j.jvsv.2014.09.005
18. Silva TC, Barrett-Connor E, Ramires JA, Mansur AP. Obesity,estrone, and coronary artery disease in postmenopausal women.Maturitas. 2008;59(3):242-248. doi:10.1016/j.maturitas.2008.01.008
19. de Oliveira TS, de Oliveira LM, de Oliveira LP, et al. Activation ofPI3K/Akt pathway mediated by estrogen receptors accounts forestrone-induced vascular activation of cGMP signaling. VasculPharmacol. 2018;110:42-48. doi:10.1016/j.vph.2018.07.003
20. Gewaltig MT, Kojda G. Vasoprotection by nitric oxide:mechanisms and therapeutic potential. Cardiovasc Res.2002;55(2):250-260. doi:10.1016/s0008-6363(02)00327-9
21. Hollingsworth SJ, Tang CB, Dialynas M, Barker SG. Varicoseveins: loss of release of vascular endothelial growth factorand reduced plasma nitric oxide. Eur J Vasc Endovasc Surg.2001;22(6):551-556. doi:10.1053/ejvs.2001.1520
Volume 4, Issue 4, 2023
Page : 302-305
_Footer